Navigation Links
Reportlinker Adds Merck KGaA: PharmaVitae Profile
Date:12/8/2010

NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Merck KGaA: PharmaVitae Profile

http://www.reportlinker.com/p0186215/Merck-KGaA-PharmaVitae-Profile.html

IntroductionThis analysis examines the historical and forecast performance for Merck KGaA in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefitsGain insight into Merck KGaA's strategic outlook across the next 6 years

Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for Merck KGaA over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answeredBenchmark Merck KGaA's performance against key rivals in the prescription pharmaceutical sector

See how Erbitux and six new launches will drive the company's sales growth

Assess the effects of Millipore on the company's non-prescription pharmaceutical sales

To order this report:: Merck KGaA: PharmaVitae Profile

More  Market Research Report

Check our  

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Reportlinker Adds Global Bladder Cancer Therapeutics Industry
2. Reportlinker Adds Global Anticoagulants Industry
3. Reportlinker Adds Global Specialty Enzymes Industry
4. Reportlinker Adds Biomarkers - Technologies, Markets And Companies
5. Reportlinker Adds Next Generation U.S. and E.U. Biomaterials/BioMedical Devices: Market Trends & Commercial Implications
6. Reportlinker Adds Immunogenicity to Biologics
7. Reportlinker Adds Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies
8. Reportlinker Adds BioMEMS 2010
9. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
10. Reportlinker Adds Breast Cancer Drug Futures
11. Reportlinker Adds Industrial Biotechnology China News 1009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... Massachusetts , September 2, 2014 ... to BioData,s research and lab management services  ... management service, is pleased to announce the appointment of ... Culot most recently served as VP Marketing and Business ... life science research and clinical applications. Previously, ...
(Date:9/1/2014)... September 01, 2014 The Collaborative ... Diagnostics report provides comprehensive understanding and unprecedented access ... into by the worlds leading life science companies. ... analysis of how and why companies enter collaborative ... prospective partner’s negotiated deals terms provides critical insight ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4
... life sciences ... ... an,agreement to acquire Recombinant Capital, Inc. (Recap), a leading life,sciences subscription ... database that provides more than 1,500,subscribers with access to over 20 ...
... 16 Scimitar Equity, LLC issues a review ... Pipeline of Niche, Cancer Therapies with Billion Dollar ... http://www.scimitarequity.com ., VioQuest Pharmaceuticals is a ... leader in the successful development of,novel drug therapies ...
... from PAREXEL,International Corporation (Nasdaq: PRXL ), a ... than 20,sessions at the Drug Information Association (DIA) ... 22 -- 26, 2008 at the Boston Convention ... global,headquarters office. PAREXEL experts will address key industry ...
Cached Biology Technology:Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm 2Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc. 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 3PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 4PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 6PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 7
(Date:9/2/2014)... professional baseball pitchers with poor core stability are more likely ... because of injury than are pitchers who have good control ... the study, 347 pitchers were assessed for lumbopelvic control during ... they raised a leg to step up were up to ... cumulative, not consecutive during the season than were ...
(Date:9/2/2014)... to prevent Type 2 diabetes, don,t get your hopes up. ... The FASEB Journal , suggests that you don,t ... study compared genetically identical twins-one heavier and one leaner-and found ... those related to Type 2 diabetes, were found in both ... the onset of this type of diabetes is largely influenced ...
(Date:9/2/2014)... the battle between our immune systems and cholera bacteria, ... known as phages. In a new study, researchers from ... National Public Health Laboratory, and elsewhere, report that phages ... in order to survive. Importantly, the study published ... escape from phage predation occurs during human infection. , ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3What you eat and not just the number of calories, is a significant factor in diabetes risk 2War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3
... (www.ucr.edu) -- Twenty-one undergraduate students in the UC Riverside Bourns ... researching everything from water quality to wildfires to materials that ... lot of opportunities to get involved with research," said Erika ... part in the Summer Bridge program. "This is the reason ...
... Tampa, Fla. (July 26, 2010) Australian ... "reprogrammed" adult mouse fat cells and neural cells to ... of different cells (pluripotency). The cells, called "induced pluripotent ... occurring pluripotent stems cells, such as embryonic stem cells, ...
... which a herpes virus invades cells has remained a mystery ... University of Pennsylvania reveals the unusual structure of a key ... to invade cells. The new map details an essential ... a new target for antiviral drugs. The research was ...
Cached Biology News:Undergrad engineers research everything from water quality to wildfires this summer 2Scientists 'reprogram' mouse fat cells into clinically useful stem cells 2A collaboration solves the herpes virus protein structure providing new drug therapy directions 2A collaboration solves the herpes virus protein structure providing new drug therapy directions 3